Table 4.
Stimuli‐responsive PEG‐hydrogel systems used for cancer therapy
| Delivery system | Loaded drug | Responsiveness | Delivery target | Application | Drug release rate | In Vivo tumor growth inhibition (TGI) |
|---|---|---|---|---|---|---|
| FPNP/Los PEG[ 30 ] | DOX | Enzyme (MMP)‐sensitive | 4T1 cells (murine breast cancer cell line) | Chemotherapy, enhanced penetration by losartan | 100% within 10 h | 59% |
| NanoDOX loaded[ 31 ] | DOX | Enzyme (MMP)‐sensitive | SCC‐15 cells (human squamous cell carcinomas cell line) | Chemotherapy | 50% within 25 days | 80% |
| HyMic[ 32 ] | Core cross‐linked (CCL) micelles | Enzyme (MMP)‐sensitive | HeLa cells (human cervical cancer cell line) | Cellular Internalization of CCL micelles by HeLa Cells | 90% within 7 days | Not applicable |
| RGDS PEG[ 33 ] | Quinacrine | Enzyme (MMP)‐sensitive | U87 MG cells (Glioblastoma multiforme cell line) | Chemotherapy | 80% within 3 days | Not applicable |
| PAMAM Dendrimers PEG[ 36 ] | DOX | Enzyme (MMP)‐sensitive | C6 cells (rat/rattus norvegicus glial tumor cell line) | Chemotherapy | 50% within 38 h | Not applicable |
| RGD PEG[ 34 ] | OPVBT | Enzyme (MMP)/photo‐ sensitive | MCF‐7, MDA‐MB‐231 cells (human breast cancer cell line) | PDT, enhanced cell attachment and spreading | Not applicable | Not applicable |
| MNHG[ 42 ] | DOX | Magnetic field/pH‐sensitive | Not applicable | Chemotherapy | 60% within 350 h | Not applicable |
| HTS‐PEG[ 43 ] | DOX | Magnetic field/pH‐sensitive | MCF‐7, 4T1 cells (human and murine breast cancer cell line) | Hyperthermia, chemotherapy | 60% within 12 h | ≈100% for MCF‐7, 85% for 4T1 |
| MSNs PEG[ 55 ] | Phosphorylated curcumin, DOX | Reduction/pH‐sensitive | HeLa cells (human cervical cancer cell line) | Chemotherapy | 80% within 25 h for phosphorylated curcumin, 70% within 25 h for DOX | Not applicable |
| PRINT®[ 56 ] | Antigenic peptide, immunostimulatory adjuvant | Reduction‐sensitive | T cells | Cancer vaccine, enhance cellular uptake | Not applicable | Not applicable |
| PEG‐DMA[ 58 ] | PTX | Photo‐sensitive | U87 MG cells (Glioblastoma multiforme cell line) | Post‐resection treatment | 30% within 6 days | Not applicable (survival time enhanced) |
| BSA‐PEG[ 60 ] | Chlorella, gold nanorods | Photo‐sensitive | 4T1 cells (murine breast cancer cell line) | Hyperthermia, tumor oxygenation, synergistic chemotherapy | Not applicable | ≈100% |
| BP@PLEL[ 62 ] | Not applicable | Photo‐sensitive | HeLa cells (human cervical cancer cell line) | Photothermal therapy, postoperative treatment of cancer | Not applicable | ≈100% |
| PEG‐GNRs[ 63 ] | PTX, gold nanorods | Photo‐sensitive | SW620 cells (human colorectal cancer cell line) | PTT, chemotherapy | 45% within 144 h | ≈100% |
| Palladium nanosheet PEG[ 64 ] | DOX | Photo‐sensitive | 4T1 cells (murine breast cancer cell line) | PTT, chemotherapy | 11 µg within 30 min | ≈100% |
| PPDl‐PPG‐PEG[ 78 ] | DOX, docetaxel | Thermo‐sensitive | Hepatoma cells | Chemotherapy | 40% within 13 days | ≈100% |
| PLGA‐PEG‐PLGA[ 79 ] | 5‐Fluorouracil, Chrysin | Thermo‐sensitive | HT29 cells (human colon cancer cell line) | Enhanced chemotherapy | 100% within 100 h for 5‐fluorouracil, 90% within 100 h for chrysin | Not applicable |
| PLGA‐PEG‐PLGA[ 80 ] | DOX | Thermo‐sensitive | Saos‐2 cells (human osteosarcoma cell line) | Chemotherapy | 60% within 15 days | 93% |
| BSA‐PEG[ 81 ] | PTX | Thermo‐sensitive | MKN45 cells (human gastric tumor cell line) | Chemotherapy | 30% within 144 h | 73% |
| PEG‐PCL‐PEG[ 82 ] | PTX | Thermo‐sensitive | HeLa cells (human cervical cancer cell line) | Chemotherapy | Not applicable | ≈50% |
| DiMC‐PEG[ 83 ] | Dimethoxycurcumin | Thermo‐sensitive | CWR22RV1 cells (human prostate cancer cell line) | Chemotherapy | 80% within 120 min | Not applicable |
| PDLLA‐PEG‐PDLLA[ 84 ] | Bevacizumab, DOX | Thermo/pH‐sensitive | HeLa cells (human cervical cancer cell line) | Enhanced chemotherapy | 73.56% for Bevacizumab, 61.21% for DOX within 36 days | 87% |
| PLA‐PEG‐PNIPAM[ 85 ] | PTX, SN‐38, R848, gemcitabine | Thermo‐sensitive | CT26 cells (murine colorectal carcinoma cell line) | Chemotherapy, immunotherapy | 100% within 15 days | ≈100% |
| PNIPAAm‐PEG[ 86 ] | DOX | Thermo‐sensitive | AT3B‐1 cells (MDR cancer cells) | Chemotherapy | 80% within 5 days | Not applicable |
| PEG–PAEUs[ 87 ] | Cisplatin | Thermo‐sensitive | A549 cells (human lung cancer cell line) | Chemotherapy | 90% within 15 days | Not applicable |
| PEG‐PBLG‐OSM[ 88 ] | Lysozyme | Thermo/pH‐sensitive | Not applicable | Not applicable | ≈250 ng mL−1 lasts for more than a week | Not applicable |
| PLGA–PEG–PLGA[ 89 ] | DOX, docetaxel | Thermo‐sensitive | H22 cells (mouse hepatocellular carcinoma cell line) | Chemotherapy | 70% within 30 days | ≈80% |
| PNIPAM‐PEG[ 90 ] | DOX | Thermo/pH‐sensitive | C26 cells (mice adenocarcinoma cell line) | Chemotherapy | 60%‐80% within 144 h | ≈83% |
| DF‐PEG‐DF[ 91 ] | DOX, DTX, Fe3O4 | Thermo‐sensitive | L929 cells (Mouse fibroblast cell line) | Chemotherapy, magnetic hyperthermia | 80% within 30 days | Not applicable |
| POR–PEG–PCL[ 99 ] | porphyrin | Thermo‐sensitive | Not applicable | In situ monitoring | Not applicable | Not applicable |
| CS/MBP/DOX[ 92 ] | DOX, Mos2/Bi2S3‐PEG | Thermo‐sensitive | L929 cells (Mouse fibroblast cell line) | Chemotherapy, PTT | 20% within 48 h | ≈75% |
| PCL‐PTSUO‐PEG[ 93 ] | DOX, ZnPc | Thermo‐sensitive | 5637 cell (human bladder cancer cell line) | Chemotherapy, PDT | 5.3% ± 2.1% for DOX, 95.2% ± 1.5% for ZnPc within 35 days | 87.50% |
| PEG‐b‐PCL[ 94 ] | PTX, Tet | Thermo‐sensitive | BGC‐823 cells, SGC‐7901cells (human low‐differentiated gastric adenocarcinoma cell line) | Chemotherapy, PDT | 50% within 5 days; 50% within 5 days | ≈70% |
| PLGA‐PEG‐PLGA[ 95 ] | DOX | Thermo‐sensitive | 4T1 cells (murine breast cancer cell line) | Chemotherapy, immunotherapy | 90% within 10 days | 86.62% |
| PELG‐PEG‐PELG[ 96 ] | DOX | Thermo‐sensitive | B16F10 cells (Mouse melanoma B16F10 cells with high metastatic cells) | Chemotherapy, immunotherapy | ≈40% within 15 days | 91.51% |
| Au‐DOX‐Gel[ 97 ] | DOX,AuNPs | Thermo‐sensitive | B16 cells (mouse melanoma), HepG2 cells (Human hepatocellular liver carcinoma) | Chemotherapy, radiotherapy | 15.7% within 24 h for DOX; 35.8% for AuNPs | 64.60% |
| PLGA‐PEG‐PLGA[ 98 ] | Gemcitabine derivative (GemC16) | Thermo‐sensitive | 4T1 cells (murine breast cancer cell line), B16F10 cells (Mouse melanoma B16F10 cells with high metastatic cells) | Chemotherapy, radiotherapy | 65 within 19 days | ≈80% |
| PCL–PEG–PCL[ 100 ] | DOX,RB | Thermo‐sensitive | BEL‐7402 cells (human liver cancer cell line) | Chemotherapy | 20% for DOX and 50% for RB within 25 h | Not applicable |
| PCN‐b‐PEG‐b‐PCN[ 101 ] | PTX | Thermo‐sensitive | 4T1 cells (murine breast cancer cell line) | Chemotherapy | 50% within 48 h | 94.27% |